ATAZANAVIR SULFATE (atazanavir) by Hetero is hiv-1 antiretroviral drug [see microbiology ( )]. First approved in 2022.
Drug data last refreshed 20h ago
HIV-1 antiretroviral drug [see Microbiology ( )].
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions
The Nitazoxanide Plus Atazanavir for COVID-19 Study
A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults
Worked on ATAZANAVIR SULFATE at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.